Opus Genetics Management
Management criteria checks 3/4
Opus Genetics' CEO is George Magrath, appointed in Nov 2023, has a tenure of 2.5 years. total yearly compensation is $1.49M, comprised of 40% salary and 60% bonuses, including company stock and options. directly owns 1.15% of the company’s shares, worth $4.31M. The average tenure of the management team and the board of directors is 2.4 years and 4 years respectively.
Key information
George Magrath
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 40.04% |
| CEO tenure | 2.5yrs |
| CEO ownership | 1.1% |
| Management average tenure | 2.4yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$1m | US$598k | -US$50m |
| Sep 30 2025 | n/a | n/a | -US$68m |
| Jun 30 2025 | n/a | n/a | -US$58m |
| Mar 31 2025 | n/a | n/a | -US$59m |
| Dec 31 2024 | US$889k | US$575k | -US$58m |
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$3m | US$96k | -US$10m |
Compensation vs Market: George's total compensation ($USD1.49M) is below average for companies of similar size in the US market ($USD2.52M).
Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.
CEO
George Magrath (40 yo)
Dr. George Magrath, MD, MBA, MS, serves as Chief Executive Officer & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$1.49m | 1.15% $ 4.3m | |
| President & Director | 1.6yrs | no data | 0.097% $ 365.1k | |
| Chief Operating Officer | 2.5yrs | US$718.41k | 0.016% $ 60.0k | |
| Chief Scientific & Development Officer | 2.3yrs | US$764.85k | 0.056% $ 209.9k | |
| CFO & Principal Accounting Officer | less than a year | no data | 0.83% $ 3.1m | |
| Chief Technology Officer | no data | no data | no data | |
| Investor Relations Officer | no data | no data | no data | |
| Senior Vice President of Corporate Development & Secretary | no data | US$789.92k | 0.16% $ 618.8k | |
| Head of Financial Quality Assurance | no data | US$789.92k | 0.060% $ 223.7k | |
| Head of Market Development & Commercialization | 4.3yrs | no data | no data | |
| Chief Medical Officer & Senior Vice President of Clinical Development | no data | no data | no data | |
| Chief Regulatory Officer | no data | no data | no data |
Experienced Management: IRD's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$1.49m | 1.15% $ 4.3m | |
| President & Director | 1.6yrs | no data | 0.097% $ 365.1k | |
| Independent Director | 5.5yrs | US$188.92k | 0.30% $ 1.1m | |
| Independent Director | 1.6yrs | US$171.44k | 0.033% $ 124.4k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 5.5yrs | US$189.45k | 0.33% $ 1.3m | |
| Independent Director | 5.5yrs | US$180.14k | 0.20% $ 736.5k | |
| Independent Chairman | 5.5yrs | US$295.97k | 2.65% $ 10.0m | |
| Lead Independent Director | 5.5yrs | US$210.14k | 0.31% $ 1.1m | |
| Director | 1.6yrs | US$168.50k | 0.22% $ 816.1k | |
| Member of Medical Advisory Board | 2.2yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
Experienced Board: IRD's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 23:27 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Opus Genetics, Inc. is covered by 14 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |